Download Files:
Products Details
Product Description
– Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
Web ID
– HY-B0280S
Shipping
– Room temperature
Molecular Formula
– C24H28D5N3O4
References
– [1]Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73.|[2]Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81.|[3]Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
CAS Number
– 1092804-87-9
Molecular Weight
– 432.57
SMILES
– CC(C=CC=C1C)=C1NC(CN(CC2)CCN2C([2H])([2H])C(O)([2H])C([2H])([2H])OC3=C(C=CC=C3)OC)=O
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease; Cancer
Solubility
– 10 mM in DMSO
Target
– Calcium Channel;Isotope-Labeled Compounds;Sodium Channel
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
